Myanmar is taking steps to increase its domestic pharmaceutical production capacity, aiming to reduce reliance on imports and better meet the healthcare needs of its population. This initiative, spearheaded by the Ministry of Industry, involves scaling up output at existing state-owned factories and the development of a new pharmaceutical industrial zone.
Currently, the country imports pharmaceuticals and medical equipment valued at approximately K400 million annually. The Myanmar Pharmaceutical Industries, operating under the Ministry of Industry, is actively working to change this dynamic. Factories in Insein, Inyaung, and Ywathagyi have been consistently increasing their productivity, resulting in a rise in local production. As of recently, these factories now fulfill 20 percent of the nation’s pharmaceutical demand, a significant increase from 10 percent in previous years.
The focus isn’t solely on bolstering existing facilities. A major component of this strategy is the planned Ngahsutaung Pharmaceutical Industrial Zone, located in Hlegu Township, Yangon Region. This ambitious project, slated for completion within two years, is designed to significantly boost domestic pharmaceutical supply. The zone aims to satisfy 50 percent of the country’s pharmaceutical needs upon completion.
Notably, the industrial zone is attracting international investment, with leading pharmaceutical companies from the United States, Spain, and Japan expected to participate. This collaboration is anticipated to bring advanced technologies and expertise to Myanmar’s pharmaceutical sector.
Beyond the Ministry of Industry’s efforts, other entities are contributing to the expansion of pharmaceutical manufacturing. Tatmadaw has established a pharmaceutical factory in Hmawby, adding to the national production capacity. Private pharmaceutical companies, including AA and Silver Shine International, are also playing a role in meeting local demand.
The Inyaung Pharmaceutical Factory is actively seeking partnerships with the private sector to expand its production of ointments, and balms. An open tender has been issued to attract interested businesses, signaling a commitment to collaborative growth within the industry.
These developments come at a crucial time for Myanmar’s healthcare system. Increasing domestic production not only reduces dependence on imports but also enhances the country’s ability to respond to public health challenges and ensure access to essential medicines for its citizens. The Ministry of Industry’s commitment, coupled with private sector involvement and international investment, suggests a concerted effort to strengthen Myanmar’s pharmaceutical landscape.
The Global New Light of Myanmar, the nation’s oldest English daily, has been reporting on these developments, providing updates on the progress of the Ngahsutaung Pharmaceutical Industrial Zone and the increasing output of state-owned factories. The publication also covered a recent rice milling technology training program, highlighting the importance of knowledge sharing and collaboration within Myanmar’s agricultural and industrial sectors. saw experts share market insights at this training.
While the current output meets 20% of local demand, the planned expansion through the Ngahsutaung Pharmaceutical Industrial Zone represents a significant step towards greater self-sufficiency. The zone’s projected contribution of an additional 30% to domestic supply will be critical in reducing the K400 million annual import bill and ensuring a more stable and accessible pharmaceutical market for the people of Myanmar.
The Ministry of Industry’s multifaceted approach – upgrading existing facilities, attracting foreign investment, and fostering public-private partnerships – demonstrates a strategic vision for the future of Myanmar’s pharmaceutical industry. Continued monitoring of these developments will be essential to assess the long-term impact on public health and economic growth.
